8 March 2024

Inspiring inclusion in healthcare

In the spirit of the theme of International Women’s Day 2024 to #inspireinclusion, we have researched some companies who are developing technologies which are making healthcare more accessible and inclusive.

Roche diagnostics

Roche diagnostics have recently had a blood test approved to assist in diagnosing polycystic ovarian syndrome (PCOS). The WHO estimates that between 8-13% of women of reproductive age have PCOS, and up to 70% of those cases are undiagnosed. Those with PCOS have increased risk of developing type 2 diabetes, heart disease, and endometrial cancer. PCOS can have symptoms overlapping with other conditions, and diagnosis usually involves a transvaginal ultrasound together with a number of blood tests and hormone profiles. The test therefore has the potential to improve the speed and accessibility of diagnosis to those with PCOS, allowing for earlier diagnosis so women can begin treatment to manage their symptoms earlier and reduce their risk of developing other associated health conditions.

Roche have pending patent applications relating to the diagnosis tool including EP application EP4127726.


Ziwig is a French biotech company who have developed a saliva based diagnostic test for endometriosis, a condition which takes on average 8 years to diagnose, and usually requires surgical procedures for diagnosis. The test utilises AI in order to analyse the saliva samples and has been found to make robust and reliable diagnoses. The time and ease with which diagnosis may now be achieved therefore allows those suffering from endometriosis to achieve a diagnosis much earlier and allow them to start managing their symptoms accordingly to improve quality of life and preserve fertility. Ziwig have a number of French patent applications directed to their AI powered diagnostics.

Béa fertility

Béa fertility are making it their mission to make fertility treatment as inclusive as possible. They provide an at home intracervical insemination system which is a more accessible option than IVF for those with fertility struggles. Founder Tess Cosad describes that “Fertility impacts one in six couples, yet access to fertility care is severely lacking globally. Fertility clinics have been selling the same expensive treatments for decades, yet there are a number of groups which remain underserved, including the LGBTQIA+ community, single people and parents experiencing secondary infertility. At Béa, our aim is to fill this gap by creating inclusive, clinical-grade fertility treatments that can be used at home”.

Béa have patent applications pending in a number of jurisdictions directed to the ICI system, including EP application EP4161414A1.

At Venner Shipley we encourage and celebrate inclusivity in healthcare, our firm, and all aspects of our lives.